Adeona's Planned Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrig's Disease is Hot Topic at 2011 California ALS Research Summit
ANN ARBOR, Mich., Sept. 30, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that its planned clinical trial of the Company's proprietary zinc-based therapy for patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, will be featured during the Hot Topics session at the 2011 California ALS Research Summit (ALS Summit) on Saturday, October 1, 2011. Todd D. Levine, M.D., President of PNA Center for Neurological Research (PNA), Assistant Clinical Professor at the University of Arizona, Co-Director of the Banner Samaritan ALS Center in Phoenix, Arizona and Lead Principal Investigator of the planned clinical trial will present the potential benefits of zinc therapy for ALS patients. Dr. Levine will also discuss preliminary data from PNA's ongoing Phase I/II open label safety study of zinc therapy in ALS patients at the ALS Summit.
"I am very excited to present our theories on the potential role of zinc in the treatment of ALS. We believe that by giving high doses of zinc to ALS patients, we can decrease the amount of toxicity from unbound glutamate and prevent neurotoxicity," said Dr. Levine. "Our goal is to improve the quality of life of patients with ALS by slowing the progression of this devastating disease."
About Amyotrophic Lateral Sclerosis (ALS)
ALS is a devastating progressive neurodegenerative disease that affects the nerve cells in the brain and the spinal cord in people of all ages and both sexes. It is estimated that as many as 30,000 Americans may have the disease at any given time. The progressive degeneration of the motor neurons in ALS eventually leads to the death of the patient. Motor neurons reach from the brain to the spinal cord and from the spinal cord to the muscles throughout the bo